Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression

A Disposable Sensor Chip Using a Paste Electrode with Surface-Imprinted Graphite Particles for Rapid and Reagentless Monitoring of Theophylline

This work focuses on a carbon-based imprinted polymer composite, employed as a molecular recognition and sensing interface in fabricating a disposable electrochemical sensor. The carbon-paste electrode was made of a molecularly imprinted polymer comprising a copolymer of methacrylic acid as the functional monomer and blended crosslinking monomers of N,N′-methylenebisacrylamide, and ethylene glycol dimethacrylate, with theophylline as the template. The analytical properties of the proposed theophylline sensor were investigated, and the findings revealed an increase in differential pulse voltammetric current compared to the non-imprinted electrode. Under optimized conditions, the sensor has shown high sensitivity, high selectivity, lower detection limit (2.5 µg/mL), and satisfactory long-term stability. Further, the sensor was tested in whole bovine blood and validated without any matrix effect and cross-reactivity. Additionally, chronoamperometry of the sensor chip supported a rapid determination of THO with a short response time of 3 s. This carbon-paste electrode is highly specific for theophylline and may be applied as a drug sensor for clinical use.

Synthetic riboswitches for the analysis of tRNA processing by eukaryotic RNase P enzymes

Removal of the 5'-leader region is an essential step in the maturation of tRNA molecules in all domains of life. This reaction is catalyzed by various RNase P activities, ranging from ribonucleoproteins with ribozyme activity to protein-only forms. In Escherichia coli, the efficiency of RNase P-mediated cleavage can be controlled by computationally designed riboswitch elements in a ligand-dependent way, where the 5'-leader sequence of a tRNA precursor is either sequestered in a hairpin structure or presented as a single-stranded region accessible for maturation. In the presented work, the regulatory potential of such artificial constructs is tested on different forms of eukaryotic RNase P enzymes-two protein-only RNase P enzymes (PRORP1 and PRORP2) from Arabidopsis thaliana and the ribonucleoprotein of Homo sapiens The PRORP enzymes were analyzed in vitro as well as in vivo in a bacterial RNase P complementation system. We also tested in HEK293T cells whether the riboswitches remain functional with human nuclear RNase P. While the regulatory principle of the synthetic riboswitches applies for all tested RNase P enzymes, the results also show differences in the substrate requirements of the individual enzyme versions. Hence, such designed RNase P riboswitches represent a novel tool to investigate the impact of the structural composition of the 5'-leader on substrate recognition by different types of RNase P enzymes.

Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers

There is a critical requirement for alternative strategies to provide the better treatment in colorectal cancer (CRC). Hence, our goal was to propose novel biomarkers as well as drug candidates for its treatment through differential interactome based drug repositioning. Differentially interacting proteins and their modules were identified, and their prognostic power were estimated through survival analyses. Drug repositioning was carried out for significant target proteins, and candidate drugs were analyzed via in silico molecular docking prior to in vitro cell viability assays in CRC cell lines. Six modules (mAPEX1, mCCT7, mHSD17B10, mMYC, mPSMB5, mRAN) were highlighted considering their prognostic performance. Drug repositioning resulted in eight drugs (abacavir, ribociclib, exemestane, voriconazole, nortriptyline hydrochloride, theophylline, bromocriptine mesylate, and tolcapone). Moreover, significant in vitro inhibition profiles were obtained in abacavir, nortriptyline hydrochloride, exemestane, tolcapone, and theophylline (positive control). Our findings may provide new and complementary strategies for the treatment of CRC.

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

This study aims to examine the clinicopathological and prognostic significance of the YKL-40 immunohistochemical expression of tumor and immune cells through human colorectal cancer (CRC) tissue. We performed immunohistochemistry for YKL-40 and investigated the clinicopathological and prognostic impact of the YKL-40 expression of tumor (T-YKL-40) and immune cells (I-YKL-40) in CRC. We also evaluated the correlation between YKL-40 and PD-L1 expression and the immunoscore. YKL-40 was expressed in 22.6% and 64.2% of T-YKL-40 and I-YKL-40, respectively, out of the 265 CRC tissues. The I-YKL-40 expression significantly correlated with well and moderately differentiated tumors. The PD-L1 expression in immune cells significantly correlated with the I-YKL-40 expression, but not T-YKL-40 expression (p = 0.020 and p = 0.846, respectively). The I-YKL-40 expression significantly correlated with a worse overall survival rate but not recurrence-free survival (p = 0.047 and p = 0.080, respectively). However, there was no significant correlation between the T-YKL-40 expression and survival. In CRCs with a high immunoscore, patients with I-YKL-40 expression demonstrated worse overall and recurrence-free survival than those without I-YKL-40 expression. Our results demonstrated that I-YKL-40 expression significantly correlated with tumor differentiation and PD-L1 expression in immune cells. I-YKL-40 expression can be useful for the prognostic stratification of CRC patients.

Circulating tumor cell count and serum CEA mRNA level predict postoperative recurrence of digestive tract cancer

OBJECTIVE

To evaluate the predictive value of circulating tumor cell count (CTC) and serum carcinoembryonic antigen (CEA) mRNA levels in postoperative recurrence of digestive tract cancer.

METHODS

A total of 52 patients with digestive tract cancer who underwent radical resection in our hospital were divided into a recurrent group (n=18) and a non-recurrent group (n=34). The CTC and CEA mRNA levels of the two groups were compared one day before the operation. Pearson correlation analysis was used to analyze the correlation between CTC and CEA mRNA levels. The curve of subjects' working characteristics was used to analyze the predictive value of the serum CTC and the level of CEA mRNA in postoperative recurrence of digestive tract cancer. The correlation of CTC and CEA mRNA expression with different age, sex, cancer type and TNM stage was further analyzed.

RESULTS

CTC and CEA mRNA levels in the recurrent group were higher than those in the non-recurrent group (P<0.05). CTC was positively correlated with the CEA mRNA level by Pearson correlation (r=0.609, P=0.000). ROC curve showed that the area under the curve of CEA mRNA, CTC and combined test in predicting postoperative recurrence of digestive tract cancer were 0.912, 0.831 and 0.965 respectively. The area under the curve of the combined test and CEA mRNA level was significantly higher than that of CTC (Z=3.794, P=0.000; Z=2.001, P=0.045). There was no significant difference in the area under the curve between combined detection and CEA mRNA (Z=1.437 and P=0.151). There was no significant difference in CTC and CEA mRNA levels among patients with different sex, age, body weight, differentiation degree and histological type (P>0.05). The CTC and CEA mRNA levels of patients in stage lll and lV were higher than those in stage l and ll and the difference was statistically significant (P<0.05). By Spearman rank correlation analysis, it was found that CTC and CEA mRNA levels were positively correlated with the TNM stage (r=0.532, 0.712, P<0.05).

CONCLUSION

levels of CTC and serum CEA mRNA have a certain value in predicting postoperative recurrence of digestive tract cancer and their expression is closely related to TNM stage. Clinical diagnosis of both of them can improve the diagnostic efficiency of predicting postoperative recurrence.

Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases

Chitinases belong to the evolutionarily conserved glycosyl hydrolase family 18 (GH18). They catalyze degradation of chitin to N-acetylglucosamine by hydrolysis of the β-(1-4)-glycosidic bonds. Although mammals do not synthesize chitin, they possess two enzymatically active chitinases, i.e., chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase), as well as several chitinase-like proteins (YKL-40, YKL-39, oviductin, and stabilin-interacting protein). The latter lack enzymatic activity but still display oligosaccharides-binding ability. The physiologic functions of chitinases are still unclear, but they have been shown to be involved in the pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer). In this review, we summarize the current knowledge about chitinases, particularly in IBDs, and demonstrate that chitinases can serve as prognostic biomarkers of disease progression. Moreover, we suggest that the inhibition of chitinase activity may be considered as a novel therapeutic strategy for the treatment of IBDs.

Selection and Characterization of YKL-40-Targeting Monoclonal Antibodies from Human Synthetic Fab Phage Display Libraries

YKL-40, also known as chitinase-3-like 1 (CHI3L1), is a glycoprotein that is expressed and secreted by various cell types, including cancers and macrophages. Due to its implications for and upregulation in a variety of diseases, including inflammatory conditions, fibrotic disorders, and tumor growth, YKL-40 has been considered as a significant therapeutic biomarker. Here, we used a phage display to develop novel monoclonal antibodies (mAbs) targeting human YKL-40 (hYKL-40). Human synthetic antibody phage display libraries were panned against a recombinant hYKL-40 protein, yielding seven unique Fabs (Antigen-binding fragment), of which two Fabs (H1 and H2) were non-aggregating and thermally stable (75.5 °C and 76.5 °C, respectively) and had high apparent affinities (K_D = 2.3 nM and 4.0 nM, respectively). Reformatting the Fabs into IgGs (Immunoglobulin Gs) increased their apparent affinities (notably, for H1 and H2, K_D = 0.5 nM and 0.3 nM, respectively), presumably due to the effects of avidity, with little change to their non-aggregation property. The six anti-hYKL-40 IgGs were analyzed using a trans-well migration assay in vitro, revealing that three clones (H1, H2, and H4) were notably effective in reducing cell migration from both A549 and H460 lung cancer cell lines. The three clones were further analyzed in an in vivo animal test that assessed their anti-cancer activities, demonstrating that the tumor area and the number of tumor nodules were significantly reduced in the lung tissues treated with H1 (IgG). Given its high affinity and desirable properties, we expect that the H1 anti-hYKL-40 mAb will be a suitable candidate for developing anti-cancer therapeutics.